Filing Details
- Accession Number:
- 0001104659-24-073623
- Form Type:
- 13G Filing
- Publication Date:
- 2024-06-19 20:00:00
- Filed By:
- Foresite Capital Fund Vi Lp
- Company:
- Casi Pharmaceuticals Inc.
- Filing Date:
- 2024-06-20
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Foresite Capital Fund VI | 1,309,383 | 1,309,383 | 1,309,383 | 9.8% | ||
| Foresite Capital Management VI | 1,309,383 | 1,309,383 | 1,309,383 | 9.8% | ||
| James Tananbaum ( Tananbaum ) | 1,309,383 | 1,309,383 | 1,309,383 | 9.8% |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d)
AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)
(Amendment No. ___________)*
CASI Pharmaceuticals, Inc.
(Name of Issuer)
Ordinary Shares, par value $0.0001
(Title of Class of Securities)
G1933S101
(CUSIP Number)
June 10, 2024
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ¨ | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| ¨ | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following pages)
Page 1 of 10
Exhibit Index on Page 9
| CUSIP # G1933S101 | Page 2 of 10 |
| 1 | NAME OF REPORTING PERSONS Foresite Capital Fund VI, L.P. (“FCF VI”) | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) x |
| 3 | SEC USE ONLY | |
| 4 | CITIZENSHIP
OR PLACE OF ORGANIZATION Delaware |
| NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 1,309,383 shares, except that Foresite Capital Management VI, LLC (“FCM VI”), the general partner of FCF VI, may be deemed to have sole power to vote these shares, and James Tananbaum (“Tananbaum”), the managing member of FCM VI, may be deemed to have sole power to vote these shares. |
| 6 | SHARED
VOTING POWER See response to row 5. | |
| 7 | SOLE DISPOSITIVE POWER 1,309,383 shares, except that FCM VI, the general partner of FCF VI, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM VI, may be deemed to have sole power to dispose of these shares. | |
| 8 | SHARED
DISPOSITIVE POWER See response to row 7. |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | 1,309,383 |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 | 9.8%1 |
| 12 | TYPE OF REPORTING PERSON | PN |
1 This percentage is calculated based upon 13,401,375 Ordinary Shares outstanding of CASI Pharmaceuticals, Inc. (the “Issuer”) as of April 28, 2024, as set forth in the Issuer’s Form F-3 Registration Statement filed with the Securities and Exchange Commission on May 3, 2024.
| CUSIP # G1933S101 | Page 3 of 10 |
| 1 | NAME OF REPORTING PERSONS Foresite Capital Management VI, LLC (“FCM VI”) | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) x |
| 3 | SEC USE ONLY | |
| 4 | CITIZENSHIP
OR PLACE OF ORGANIZATION Delaware |
| NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 1,309,383 shares, all of which are directly owned by FCF VI. FCM VI, the general partner of FCF VI, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM VI, may be deemed to have sole power to vote these shares. |
| 6 | SHARED
VOTING POWER See response to row 5. | |
| 7 | SOLE DISPOSITIVE POWER 1,309,383 shares, all of which are directly owned by FCF VI. FCM VI, the general partner of FCF VI, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM VI, may be deemed to have sole power to dispose of these shares. | |
| 8 | SHARED
DISPOSITIVE POWER See response to row 7. |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | 1,309,383 |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 | 9.8%2 |
| 12 | TYPE OF REPORTING PERSON | OO |
2 This percentage is calculated based upon 13,401,375 Ordinary Shares outstanding of CASI Pharmaceuticals, Inc. (the “Issuer”) as of April 28, 2024, as set forth in the Issuer’s Form F-3 Registration Statement filed with the Securities and Exchange Commission on May 3, 2024.
| CUSIP # G1933S101 | Page 4 of 10 |
| 1 | NAME OF REPORTING PERSONS James Tananbaum (“Tananbaum”) | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) x |
| 3 | SEC USE ONLY | |
| 4 | CITIZENSHIP
OR PLACE OF ORGANIZATION United States |
| NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 1,309,383 shares, all of which are directly owned by FCF VI. Tananbaum is the managing member of FCM VI, which is the general partner of FCF VI. Tananbaum may be deemed to have sole power to vote these shares. |
| 6 | SHARED
VOTING POWER See response to row 5. | |
| 7 | SOLE DISPOSITIVE POWER 1,309,383 shares, all of which are directly owned by FCF VI. Tananbaum is the managing member of FCM VI, which is the general partner of FCF VI. Tananbaum may be deemed to have sole power to dispose of these shares. | |
| 8 | SHARED
DISPOSITIVE POWER See response to row 7. |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | 1,309,383 |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 | 9.8%3 |
| 12 | TYPE OF REPORTING PERSON | IN |
3 This percentage is calculated based upon 13,401,375 Ordinary Shares outstanding of CASI Pharmaceuticals, Inc. (the “Issuer”) as of April 28, 2024, as set forth in the Issuer’s Form F-3 Registration Statement filed with the Securities and Exchange Commission on May 3, 2024.
| CUSIP # G1933S101 | Page 5 of 10 |
| ITEM 1(A). | NAME OF ISSUER |
CASI Pharmaceuticals, Inc. (the “Issuer”)
| ITEM 1(B). | ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES |
1701-1702, China Central Office Tower 1 No. 81 Jianguo Road, Chaoyang District, Beijing, 100025 People’s Republic of China. |
| ITEM 2(A). | NAME OF PERSONS FILING
This Schedule is filed by Foresite Capital Fund VI, L.P., a Delaware limited partnership (“FCF VI”), Foresite Capital Management VI, LLC, a Delaware limited liability company (“FCM VI”) and James Tananbaum. The foregoing entities and individuals are collectively referred to as the “Reporting Persons.” |
| ITEM 2(B). | ADDRESS OF PRINCIPAL OFFICE |
| The address for each of the Reporting Persons is: | |
| c/o Foresite Capital Management | |
| 900 Larkspur Landing Circle, Suite 150 | |
| Larkspur, CA 94939 |
| ITEM 2(C). | CITIZENSHIP
See Row 4 of cover page for each Reporting Person. |
| ITEM 2(D). | TITLE OF CLASS OF SECURITIES
Ordinary Shares, par value $0.0001 |
| ITEM 2(E) | CUSIP NUMBER
G1933S101 |
| ITEM 3. | If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
Not applicable. |
| CUSIP # G1933S101 | Page 6 of 10 |
| ITEM 4. | OWNERSHIP |
The following information with respect to the ownership of the Ordinary Shares of the Issuer by the persons filing this Statement is provided as of June 10, 2024:
| (a) | Amount beneficially owned: See Row 9 of cover page for each Reporting Person. |
| (b) | Percent of Class: See Row 11 of cover page for each Reporting Person. |
| (c) | Number of shares as to which such person has: |
| (i) | Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person. |
| (ii) | Shared power to vote or to direct the vote: |
See Row 6 of cover page for each Reporting Person.
| (iii) | Sole power to dispose or to direct the disposition of: |
See Row 7 of cover page for each Reporting Person.
| (iv) | Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person. |
| ITEM 5. | OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS Not applicable. |
| ITEM 6. | OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. Under certain circumstances set forth in the limited partnership agreement of FCF VI and the limited liability company agreement of FCM VI, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member. |
| ITEM 7. | IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY Not applicable. |
| ITEM 8. | IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. Not applicable |
| ITEM 9. | NOTICE OF DISSOLUTION OF GROUP. Not applicable |
| CUSIP # G1933S101 | Page 7 of 10 |
| ITEM 10. | CERTIFICATION. By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. |
| CUSIP # G1933S101 | Page 8 of 10 |
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: June 20, 2024
| FORESITE CAPITAL FUND VI, L.P. | ||
| By: | FORESITE CAPITAL MANAGEMENT VI, LLC | |
| Its: | General Partner | |
| By: | /s/ James Tananbaum | |
| Name: | James Tananbaum | |
| Title: | Managing Member | |
| FORESITE CAPITAL MANAGEMENT VI, LLC | ||
| By: | /s/ James Tananbaum | |
| Name: | James Tananbaum | |
| Title: | Managing Member | |
| JAMES TANANBAUM | ||
| By: | /s/ James Tananbaum | |
| Name: | James Tananbaum | |
| CUSIP # G1933S101 | Page 9 of 10 |
EXHIBIT INDEX
Found on Sequentially | |
| Exhibit | Numbered Page |
| Exhibit A: Agreement of Joint Filing | 10 |
| CUSIP # G1933S101 | Page 10 of 10 |
exhibit A
Agreement of Joint Filing
The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary Shares of the Issuer shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.
Date: June 20, 2024
| FORESITE CAPITAL FUND VI, L.P. | ||
| By: | FORESITE CAPITAL MANAGEMENT VI, LLC | |
| Its: | General Partner | |
| By: | /s/ James Tananbaum | |
| Name: | James Tananbaum | |
| Title: | Managing Member | |
| FORESITE CAPITAL MANAGEMENT VI, LLC | ||
| By: | /s/ James Tananbaum | |
| Name: | James Tananbaum | |
| Title: | Managing Member | |
| JAMES TANANBAUM | ||
| By: | /s/ James Tananbaum | |
| Name: | James Tananbaum | |